Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

NCT00903110 is registered in ClinicalTrials.gov with Esteve Pharmaceuticals, S.A. as lead sponsor.

NCT NCT00903110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00903110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Lead sponsor
Esteve Pharmaceuticals, S.A.
Phase
Observational
Overall status
Recruiting
Start date
December 9, 2008
Completion date
December 31, 2027
Enrollment
500 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

igf1 deficiency